Literature DB >> 24165034

Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis.

Meng Qian1, Michelle W Ma, Nathaniel H Fleming, Daniel J Lackaye, Eva Hernando, Iman Osman, Yongzhao Shao.   

Abstract

To better identify melanoma patients who are, at the time of primary melanoma diagnosis, at high risk of developing brain metastases, primary melanoma characteristics were examined as risk factors for brain metastasis development. In a study of two patient cohorts, clinicopathological characteristics prospectively collected at primary cutaneous melanoma diagnosis for patients with/without brain metastasis were assessed in univariate and multivariate analyses using data from two prospectively collected databases: the Melanoma Cooperative Group (MCG) (1972-1982) and the Interdisciplinary Melanoma Cooperative Group (IMCG) (2002-2009). Candidate risk factors were evaluated in association with time to brain metastasis using either the log-rank test or Cox proportional hazards regression analysis with/without considering competing risks. Out of 2341 total patients included in the study, 222 (9.5%) developed brain metastases (median follow-up: 98 months). The median time to brain metastases was 30.5 months and the median survival time after brain metastases was 4 months. Increased hazard ratios (HRs) for brain metastasis were found among thicker (logarithmic value in mm) (MCG: HR=1.97, P<0.0001; IMCG: HR=1.31, P=0.018), ulcerated (MCG: HR=1.93, P=0.01; IMCG: HR=3.14, P<0.0001), and advanced-stage (MCG: HR=2.08, P=0.008; IMCG: HR=2.56, P=0.0002) primary melanomas on the basis of multivariate Cox regression analysis assuming the presence of competing risks. Primary cutaneous melanoma thickness, ulceration, and stage were identified and validated as risk factors associated with time to melanoma brain metastasis.

Entities:  

Mesh:

Year:  2013        PMID: 24165034      PMCID: PMC4419696          DOI: 10.1097/CMR.0000000000000015

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  20 in total

1.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

3.  Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma.

Authors:  Benjamin E Saltman; Ian Ganly; Snehal G Patel; Daniel G Coit; Mary Sue Brady; Richard J Wong; Jay O Boyle; Bhuvanesh Singh; Ashok R Shaha; Jatin P Shah; Dennis H Kraus
Journal:  Head Neck       Date:  2010-12       Impact factor: 3.147

4.  Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Authors:  Agop Y Bedikian; Caimiao Wei; Michelle Detry; Kevin B Kim; Nicholas E Papadopoulos; Wen-Jen Hwu; Jade Homsi; Michael Davies; Susan McIntyre; Patrick Hwu
Journal:  Am J Clin Oncol       Date:  2011-12       Impact factor: 2.339

5.  Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).

Authors:  Elizabeth Zettersten; Richard W Sagebiel; James R Miller; Sreedhar Tallapureddy; Stanley P L Leong; Mohammed Kashani-Sabet
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

6.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

Authors:  J H Sampson; J H Carter; A H Friedman; H F Seigler
Journal:  J Neurosurg       Date:  1998-01       Impact factor: 5.115

7.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.

Authors:  Thomas K Eigentler; Adina Figl; Dietmar Krex; Peter Mohr; Cornelia Mauch; Knut Rass; Azize Bostroem; Oliver Heese; Oliver Koelbl; Claus Garbe; Dirk Schadendorf
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

8.  Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.

Authors:  Jan Zakrzewski; Laurel N Geraghty; Amy E Rose; Paul J Christos; Madhu Mazumdar; David Polsky; Richard Shapiro; Russell Berman; Farbod Darvishian; Eva Hernando; Anna Pavlick; Iman Osman
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

9.  Central nervous system metastases of cutaneous malignant melanoma--a population-based study.

Authors:  G Cohn-Cedermark; E Månsson-Brahme; L E Rutqvist; O Larsson; H Johansson; U Ringborg
Journal:  Acta Oncol       Date:  1998       Impact factor: 4.089

10.  Serum microRNAs as biomarkers for recurrence in melanoma.

Authors:  Erica B Friedman; Shulian Shang; Eleazar Vega-Saenz de Miera; Jacob Ulrik Fog; Maria Wrang Teilum; Michelle W Ma; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Eva Hernando; Adam Baker; Yongzhao Shao; Iman Osman
Journal:  J Transl Med       Date:  2012-08-02       Impact factor: 5.531

View more
  10 in total

Review 1.  Management of melanoma brain metastases.

Authors:  Mary Frances McAleer; Dae W Kim; Van A Trinh; Wen-Jen Hwu
Journal:  Melanoma Manag       Date:  2015-08-10

2.  Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Authors:  Laura J Gardner; Morgan Ward; Robert H I Andtbacka; Kenneth M Boucher; Glen M Bowen; Tawnya L Bowles; Adam L Cohen; Kenneth Grossmann; Ying J Hitchcock; Sheri L Holmen; John Hyngstrom; Hung Khong; Martin McMahon; Marcus M Monroe; Carolyn B Ross; Gita Suneja; David Wada; Douglas Grossman
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

3.  Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.

Authors:  Ellen H de Moll; Yichun Fu; Yingzhi Qian; Sara H Perkins; Shira Wieder; Sacha Gnjatic; Romain Remark; Sebastian G Bernardo; Marina Moskalenko; Jonathan Yao; Tammie Ferringer; Rui Chang; Jerry Chipuk; Basil A Horst; Miriam B Birge; Robert G Phelps; Yvonne M Saenger
Journal:  Cancer Immunol Immunother       Date:  2015-06-16       Impact factor: 6.968

4.  Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma.

Authors:  Justin Rendleman; Matjaz Vogelsang; Anuj Bapodra; Christina Adaniel; Ines Silva; Duane Moogk; Carlos N Martinez; Nathaniel Fleming; Jerry Shields; Richard Shapiro; Russell Berman; Anna Pavlick; David Polsky; Yongzhao Shao; Iman Osman; Michelle Krogsgaard; Tomas Kirchhoff
Journal:  J Med Genet       Date:  2015-01-20       Impact factor: 6.318

5.  The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis.

Authors:  Matjaz Vogelsang; Carlos N Martinez; Justin Rendleman; Anuj Bapodra; Karolina Malecek; Artur Romanchuk; Esther Kazlow; Richard L Shapiro; Russell S Berman; Michelle Krogsgaard; Iman Osman; Tomas Kirchhoff
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

Review 6.  Brain metastasis: Unique challenges and open opportunities.

Authors:  Frank J Lowery; Dihua Yu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-12-06       Impact factor: 10.680

Review 7.  Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter.

Authors:  Torben Redmer
Journal:  Mol Cancer       Date:  2018-07-27       Impact factor: 27.401

8.  Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM).

Authors:  Robert Ferguson; Alexi Archambault; Danny Simpson; Leah Morales; Vylyny Chat; Esther Kazlow; Rebecca Lax; Garrett Yoon; Una Moran; Richard Shapiro; Anna Pavlick; David Polsky; Iman Osman; Tomas Kirchhoff
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

9.  High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Authors:  Wolfram E Samlowski; James Moon; Merle Witter; Michael B Atkins; John M Kirkwood; Megan Othus; Antoni Ribas; Vernon K Sondak; Lawrence E Flaherty
Journal:  Cancer Med       Date:  2017-10-10       Impact factor: 4.452

10.  Predictive value of a nomogram for melanomas with brain metastases at initial diagnosis.

Authors:  Hong Liu; Yan-Bo Xu; Cheng-Cheng Guo; Ming-Xin Li; Jia-Li Ji; Rong-Rong Dong; Ling-Ling Zhang; Xue-Xin He
Journal:  Cancer Med       Date:  2019-10-27       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.